Single-center,retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer

Abstract

Introduction

The safety and efficacy of direct oral anticoagulants in cancer patients is currently unclear. Low-molecular-weight heparin remains the standard of care for cancer patients with venous thromboembolism, with warfarin, a vitamin K antagonist, as an alternative. Clear recommendations do not exist for patients with both active cancer and non-valvular atrial fibrillation. The objectives of this study were to report safety and efficacy outcomes of direct oral anticoagulants, low-molecular-weight heparin, and vitamin K antagonist in cancer patients with venous thromboembolism or non-valvular atrial fibrillation.

Methods

Retrospective chart review of adult cancer patients from 2012 to 2015 who received an antineoplastic agent and an anticoagulant.

Results

A total of 258 patients were reviewed: 80 patients in direct oral anticoagulant group, 95 patients in low-molecular-weight heparin group, and 83 patients in vitamin K antagonist group. Sixty-seven percent of patients were on an anticoagulant for acute or chronic venous thromboembolism. Major bleeding events were similar across the groups (15% direct oral anticoagulant vs 17% low-molecular-weight heparin vs 18% vitamin K antagonist). The most common type of major bleeding event was gastrointestinal bleeding. A total of five fatal bleeding events occurred. Venous thromboembolism recurrence rates were higher in both direct oral anticoagulant (18%) and low-molecular-weight heparin (12%) groups while lower in vitamin K antagonist group (10%) compared to previous studies.

Conclusions

Cancer patients receiving direct oral anticoagulants, low-molecular-weight heparin, or vitamin K antagonist had similar rates of major bleeding events, with gastrointestinal bleeding being the most common event. Venous thromboembolism recurrence rates were higher in direct oral anticoagulant and low-molecular-weight heparin groups than prior studies. Randomized trials are warranted to establish clear safety and efficacy in this population.

Keywords

Direct oral anticoagulants enoxparin cancer hemorrhage venous thromboembolism

Get full access to this article

View all access options for this article.

References

Pfizer Inc. Eliquis [package insert]. New York, NY: Pfizer Inc., 2016.

Daiichi Sankyo, Inc. Savaysa [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc., 2015.

Janssen Pharmaceuticals, Inc. Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc., 2016.

Boeringer Ingelhein Pharmaceuticals, Inc. Pradaxa [package insert]. Ridgefield, CT: Boeringer Ingelheim Pharmaceuticals, Inc., 2015.

Schulman

Kearon

Kakkar

et al.

Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–2352.

Bauersachs

Berkowitz

Brenner

et al.

Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–2510.

Buller

Prins

Lensin

et al.

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287–1297.

Agnelli

Buller

Cohen

et al.

Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699–708.

The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 799–808.

10.

Connolly

Ezekowitz

Yusuf

et al.

the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.

11.

Patel

Mahaffey

Garg

et al.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.

12.

Granger

Alexander

McMurray

JJV

et al.

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–992.

13.

Giugliano

Ruff

Braunwald

et al.

Edoxaban versus Warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–2104.

14.

Kearon

Aki

Ornelas

et al.

Antithrombotic therapy for VTE disease. Chest 2016; 149: 315–352.

15.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Cancer-associated venous thromboembolic disease. Version 1.2017, www.nccn.org/professionals/physician_gls/pdf/vte.pdf (accessed 24 July 2017).

16.

Lyman

Bohlke

Khorana

et al.

American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol 2015; 33: 654–656.

17.

Mandalà

Falanga

Roila

. Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol 2011; 22: vi85–92.

18.

Lee

Levine

Baker

et al.

Low-molecular-weight heparin versus a coumadin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–153.

19.

Lee

Kamphuisen

Meyer

et al.

Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314: 677–686.

20.

Hull

Pineo

Brant

et al.

Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062–1072.

21.

Meyer

Marjanovic

Valcke

et al.

Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729–1735.

22.

Deitcher

Kessler

Merli

et al.

Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12: 389–396.

23.

Carrier

Cameron

Delluc

et al.

Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res 2014; 134: 1214–1219.

24.

Vedovati

Germini

Agnelli

et al.

Direct oral anticoagulants in patients with VTE and cancer. Chest 2015; 147: 475–483.

25.

Posch

Königsbrügge

Zielinski

et al.

Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 2015; 136: 582–589.

26.

January

Wann

Alpert

et al.

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol 2014; 64: 2246–2280.

27.

Ross

Miller

Hernandez

. OC-13 Safe and effective use of direct oral anticoagulants (DOAC) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism. Thromb Res 2016; 140: S173–S174.

28.

Bott-Kitslaar

Saadiq

McBane

et al.

Efficacy and safety of rivaroxaban in patients with venous thromboembolism and active malignancy: a single-center registry. Am J Med 2016; 129: 615–619.

29.

Theberge

Bowdridge

Forgie

et al.

Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease. Thromb Res 2017; 152: 4–6.

30.

Rosendaal

Cannegieter

van der Meer

et al.

A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236–239.

31.

Schulman

Kearon

. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692–694.

32.

Young

Phillips

Hancocks

et al.

OC-11 Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thromb Res 2016; 140: S172–S173.

33.

Assistance Publique - Hôpitaux de Paris. Cancer associated thrombosis, a pilot treatment study using rivaroxaban (CASTA-DIVA). In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT02746185 (2000, accessed 1 April 2017).

34.

AIO-Studien-gGmbH. Rivaroxaban in the treatment of venous thromboembolism (VTE) in cancer patients. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT02583191 (2000, accessed 1 April 2017).

35.

Bayer. A non-interventional study on xarelto for treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in patients with active cancer (COSIMO). In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT02742623 (2000, accessed 1 April 2017).

36.

M.D. Anderson Cancer Center. Rivaroxaban Utilization for treatment and prevention of thromboembolism in cancer patients: experience at a comprehensive cancer center. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT02502396 (2000, accessed 2 April 2017).

37.

Samsung Medical Center. Anticoagulation in cancer related stroke (OASIS-CANCER). In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT02743052 (2000, accessed 2 April 2017).

38.

Academic and Community Cancer Research United. Apixaban or dalteparin in reducing blood clots in patients with cancer related venous thromboembolism. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US). Available from: https://clinicaltrials.gov/ct2/show/NCT02585713 (2000, accessed 2 April 2017).

39.

University Hospital, Akershus. Apixaban as treatment of venous thrombosis in patients with cancer: the CAP Study (CAP). In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT02581176 (2000, accessed 2 April 2017).

40.

Fadoi Foundation, Italy. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT03045406 (2000, accessed 2 April 2017).

41.

Daiichi Sankyo Inc. Cancer venous thromboembolism (VTE). In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT02073682 (2000, accessed 2 April 2017).

42.

Alliance Foundation Trials, LLC. CANVAS: Direct oral anticoagulants (DOACs) versus LMWH±warfarin for VTE in cancer. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT02744092 (2000, accessed 2 April 2017).

43.

G. d'Annunzio University. Prospective study on the treatment of unsuspected pulmonary embolism in cancer patients. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT01727427 (2000, accessed 2 April 2017).